Answers are grounded in this paper and cite their sources.
Acute respiratory distress syndrome (ARDS) remains to be a paramount healthcare issue, frequently resulting in respiratory failure and death. Recently, the rapidly expanding knowledge about the pathophysiology of novel severe acute respiratory syndrome (nSARS-CoV-2) infection provides a significant insight regarding the implication of cytokines storm, which mainly causes an acute lung injury (ALI) in COVID-19 patients and directs the disease severity. As hypoxemia worsens, ALI can progress into ARDS leading to a high mortality rate. Despite advances in clinical care, the lungs of a subset of ARDS survivors show persistent fibrotic changes triggered by an imbalance between higher reactive oxidative species and lower anti-oxidative substrates. Clinical evidence have shown the pneumoprotective effects of quercetin in certain pulmonary conditions. Albeit many studies evaluating quercetin's anti-inflammatory action on bacterial lipopolysaccharide-induced models have been done, anti-inflammatory studies using viral-induced models or its surrogate are still lacking. In this review, the authors discuss the possible molecular mechanism of quercetin in targeting specific pathways in lung injury and its sequelae, including pulmonary fibrosis that is induced both by infectious and pneumotoxic agents.
No takes yet. Share an insight, caveat, or question.
Rizky et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: